Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio, Inc. is poised for a positive outlook due to its innovative cell therapy pipeline focused on autologous tumor infiltrating lymphocyte therapies and its development of genetically engineered TIL therapies through the CoStAR platform. The key asset, ITIL-306, addresses a wide range of solid tumors, including ovarian and renal cancers, positioning the company to tap into substantial market opportunities as treatment options expand. Additionally, the broader success of related therapies, as evidenced by encouraging data from studies such as HARMONi, may create a supportive environment for Instil Bio's advancements and encourage investor confidence in the potential for growth.

Bears say

Instil Bio Inc faces significant investor skepticism, particularly due to the perceived underwhelming shift in overall survival (OS) curves reported in recent updates, which has led bearish investors to focus on this aspect. The company is also confronted with multiple risks, including potential delays in clinical assessments and the possibility of failing to produce positive clinical data, notably for its candidate, AXN-2510, in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Additionally, there are concerns regarding medium- to long-term dilution risks, further contributing to a negative outlook on the stock’s future performance.

Instil Bio (TIL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.